Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU.Results of a phase II trial

Pouillart, P; Mathé, G; Thy, Thao Hoang; Lhéritier, J; Poisson, M; Huguenin, P; Gauthier, H.; Morin, P; Parrot, R.

doi:10.1002/1097-0142(197611)38:5<1909::aid-cncr2820380507>3.0.co;2-q

Cited by 26 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nitrosoureas are considered the most active chemotherapeutic agents in brain tumors, achieving a single agent response rate of nearly 50% (25,26). In combination, response rates as high as 72% have been reported (27). However duration of response is generally short (3-6 months), and randomized studies of chemotherapy with nitrosoureas and/or radiotherapy for the treatment of malignant gliomas after surgery still show very slight improvement in mean survival (29).…”

Section: Discussionmentioning

confidence: 99%

Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma

Maral

Poisson

et al. 1985

J Neuro-Oncol

View full text Add to dashboard Cite

Diaziquone, a new alkylating agent which crosses the blood brain barrier, has shown a 20% response rate in phase II studies in heavily pretreated patients. We have treated 23 patients at our institution as part of a multicentric phase II European trial of diaziquone. All had histologically proven malignant glioma unequivocally progressing on CT scan. Prior therapy had consisted of surgical excision (13 patients), cobalt radiotherapy to CNS (13 patients), and chemotherapy with nitrosourea derivatives (11 patients). Six patients had no prior therapy. Median age was 42 years (range 22-69) and performance status was 3+ or better. They were treated with monthly courses of diaziquone 5.5 mg/m2 I.V. (10 min.) X 5 days. Dosage adjustments were made according to leucocyte and platelet nadirs. Thrombocytopenia was the dose limiting toxicity. Very mild gastrointestinal toxicity was observed. One patient developed hemolytic anemia. One complete response (clinical and CT scan), 7 partial clinical responses (3: greater than 50%, 4: 25-50%), and 1 disease stabilization (less than 25%) were documented. The longest response has now lasted over 26 months. These preliminary results show that chemotherapy with diaziquone can achieve a response rate as high as 35% in malignant glioma even in patients previously treated with a chemotherapy regimen including a nitrosourea (four of the seven objective responses were seen in such patients). Diaziquone is well tolerated and deserves further study in the management of malignant glioma.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma

Maral

Poisson

et al. 1985

J Neuro-Oncol

View full text Add to dashboard Cite

show abstract

Intra-arterial BCNU therapy in the treatment of metastatic brain tumor from lung carcinoma.A preliminary report

Yamada

Bremer

West

et al. 1979

Cancer

View full text Add to dashboard Cite

Nine patients with intracerebral metastasis from lung carcinoma were treated with intracarotid and intravertebral artery infusion of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Four of these patients considered definite responders showed unequivocal clinical improvement and definite decreases in the size of tumors evaluated by neurologic examination, computerized tomographic (CT) scan and radionuclide brain scan (RBS). One patient's clinical condition stabilized with doubtful improvement of diagnostic tests (probable responder). The remaining four patients had further unfavorable progression of the clinical and scan findings and were clearly nonresponders. Complications were transient and included: local pain in the eye, orbit, and occipital-nuchal area during infusion in 7 patients, focal seizure in 3 patients, mild confusion with disorientation in 2 patients, and nausea in 2 patients. Our findings suggest that intra-arterial BCNU therapy may be effective and may be used as an adjuvant to surgery and/or radiotherapy for the treatment of metastatic brain tumor from lung carcinoma.

show abstract

Cerebral metastases as first symptom of bronchogenic carcinoma. A prospective study of 37 cases

Trillet

Catajar

Cordier

et al. 1991

Cancer

View full text Add to dashboard Cite

Among the patients showing evidence of cerebral metastases without previously known cancer history, lung cancer has been found 37 times as the primary tumor in our institution. There were 34 men and three women and all but two were heavy smokers. Only one presented at diagnosis with thoracic symptoms but the chest radiograph was abnormal in 34. The histologic type of the primary tumor was obtained in 32 cases as a result of thoracic investigations and in five cases from metastatic tumor tissue. The primary tumor appeared to be non-small cell lung carcinoma in 26 cases and small cell lung carcinoma in 11 cases. These results show that patients treated with surgery (20 cases) have a better survival (median 10 months versus 4.5) than the others, and among surgically treated patients only those treated with bifocal resection (eight patients) are long-term survivors. Also, in four of six patients, objective regression of the neurologic symptoms was seen after radiation therapy alone. Central nervous system relapse was seen in 12 patients, but in none of the patients treated with postoperative radiation therapy. Conventional chemotherapy (11 patients) induced objective responses only in the small cell type and proved to be too toxic when used simultaneously with radiation therapy in inoperable patients.

show abstract

Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU.Results of a phase II trial

Cited by 26 publications

References 9 publications

Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma

Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma

Intra-arterial BCNU therapy in the treatment of metastatic brain tumor from lung carcinoma.A preliminary report

Cerebral metastases as first symptom of bronchogenic carcinoma. A prospective study of 37 cases

Contact Info

Product

Resources

About